HONG KONG and NANJING, China, Sept. 20, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc. a clinical-stage biopharmaceutical company today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for its HPG7233, an agonist of Thyroid Hormone Receptor beta (THR-?) for the treatment of patients with non-alcoholic steatohepatitis (NASH) and dyslipidemia.
SHANGHAI, May 25, 2023 /PRNewswire/ -- Hepagene Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on developing novel therapies for patients with chronic liver diseases, today announced that Hepagene will present two posters highlighting the preclinical and clinical development for its two non-alcoholic steatohepatitis (NASH) programs at the European Association for the Study of the Liver (EASL) Congress, taking place in Vienna Austria, June 21-24, 2023. Details of the presentation are as follows:
Hepagene Therapeutics has commenced the Phase IIa RISE clinical trial ofnHPG1860 to treat non-alcoholic steatohepatitis (NASH) patients.
SHANGHAI, Dec. 2, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on innovative therapies for patients with liver diseases, today announced that it has screened the first patient in the USA for the RISE study, a Phase IIa clinical trial of HPG1860 in patients with non-alcoholic steatohepatitis (NASH). HPG1860, a non-bile acid, potent, selective and full farnesoid X receptor (FXR) agonist, is under development for the treatment of NASH and cholestatic hepatitis.
SHANGHAI, Aug. 23, 2021 /PRNewswire/ -- Hepagene Therapeutics, Inc., a clinical stage biopharmaceutical company focusing on novel therapies for patients with liver diseases, today announced positive results from its Phase I study of HPG1860 conducted in the United States. HPG1860 is a non-bile acid, potent, selective and full FXR agonist being developed for treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). Findings show that treatment with HPG1860 was safe, well-tolerated and demonstrated a robust target engagement with a favorable pharmacokinetic (PK) profile after 14 days of once daily dosing in healthy volunteers. Detailed results will be presented at upcoming AASLD international liver conference.